.jpg "Editas Medicine Inc (NASDAQ: EDIT)")
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Editas Medicine Inc (EDIT), with a price target of $55. The company’s shares closed on Friday at $26.14.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 15.4% and a 46.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Logicbio Therapeutics Inc.
Currently, the analyst consensus on Editas Medicine Inc is a Moderate Buy with an average price target of $55.
See today’s analyst top recommended stocks >>
Based on Editas Medicine Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.24 million. In comparison, last year the company had a GAAP net loss of $36.19 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).
